As Purdue Pharma grapples with thousands of lawsuits blaming the company for contributing to the opioid crisis, the drug maker has signaled it may file bankruptcy. If that happens, some newly created subsidiaries are likely to come under scrutiny.

Over the past several months, Purdue has launched two limited partnerships that are now marketing or developing drugs that were previously listed as part of the Purdue product portfolio. Several current and former Purdue executives run these companies, both of which the drug maker refers to as operating subsidiaries. And a Purdue entity holds trademark rights for their names.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • The article should state that there is not a relationship between Purdue Pharma and Purdue University.

  • The Sacklers wholesaled opiates to Americans, with the help of the regulators. They lied about their product, and created a false narrative, which the media is still following to cover their tracks. So far the only people punished, where the DEA agents who tried to enforce the law. They will at least try to get away with hiding their assets, it is the American way. They have gotten away with all of it for this long.

  • Quite a turn of phrase – “In legal parlance, such concerns are known as fraudulent conveyance” – mr ed. Now what kind of noble and upstanding corporate entity would attempt such a thing? (Rhetorical question – or “April Fools?)

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy